Advertisement
Mayo Clinic Proceedings Home

Effect of Preprocedural Thrombocytopenia on Prognosis After Percutaneous Coronary Intervention

      Abstract

      Objective

      To assess early and late outcomes, including bleeding, in patients with thrombocytopenia undergoing percutaneous coronary intervention (PCI).

      Patients and Methods

      We performed a retrospective single-center study of patients with preprocedural thrombocytopenia (platelet count ≤100,000/μL; n=204) undergoing PCI between 2003 and 2015. Inhospital and late outcomes were compared with those of a matched control group without thrombocytopenia (n=1281).

      Results

      The most common causes of thrombocytopenia were liver disease, immune-mediated disease, and hematologic malignant neoplasms. Inhospital bleeding events after PCI were similar in patients with thrombocytopenia and matched controls (24 of 146 [16.4%] vs 179 of 1281 [14.0%]; P=.40) and were largely classified as minor using the Bleeding Academic Research Consortium (BARC) classification (89% BARC 1 or 2). There was no significant difference in inhospital death (4 of 146 [2.7%] vs 71 of 1281 [2.0%]; P=.56), but patients with thrombocytopenia had higher rates of platelet and red blood cell transfusion (18 of 146 [12.3%] vs 93 of 1281 [7.2%]; P=.05). During long-term follow-up, Kaplan-Meier estimated rates of bleeding events (BARC ≥2) were higher for thrombocytopenia (at 5 years, 7.9% vs 3.6%; P=.03). Patients with thrombocytopenia had a similar risk of long-term cardiac mortality, but significantly higher rates of noncardiac mortality (at 5 years, 28% vs 21%; P=.02).

      Conclusion

      This study suggests that short-term outcomes after PCI in patients with thrombocytopenia were favorable. On long-term follow-up, thrombocytopenia was associated with a higher risk of long-term noncardiac mortality and bleeding.

      Abbreviations and Acronyms:

      BARC (Bleeding Academic Research Consortium), CABG (coronary artery bypass graft), DES (drug-eluting stent), Gp (glycoprotein), INR (international normalized ratio), MI (myocardial infarction), PCI (percutaneous coronary intervention)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chhatriwalla A.K.
        • Amin A.P.
        • Kennedy K.F.
        • et al.
        National Cardiovascular Data Registry. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention.
        JAMA. 2013; 309 ([published correction appears in JAMA. 2013;310(6):647]): 1022-1029
        • Rao S.V.
        • Dai D.
        • Subherwal S.
        • et al.
        Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients.
        JACC Cardiovasc Interv. 2012; 5 ([published correction appears in JACC Cardiovasc Interv. 2012;5(11):1192]): 958-965
        • Zeidler K.
        • Arn K.
        • Senn O.
        • Schanz U.
        • Stussi G.
        Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia.
        Transfusion. 2011; 51: 2269-2276
        • Astwood E.
        • Vora A.
        Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukaemia.
        Br J Haematol. 2011; 152: 505-511
        • van Veen J.J.
        • Nokes T.J.
        • Makris M.
        The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals.
        Br J Haematol. 2010; 148: 15-25
        • Merlini P.A.
        • Rossi M.
        • Menozzi A.
        • et al.
        Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
        Circulation. 2004; 109: 2203-2206
        • Salengro E.
        • Mulvihill N.T.
        • Farah B.
        Acute profound thrombocytopenia after use of eptifibatide for coronary stenting.
        Catheter Cardiovasc Interv. 2003; 58: 73-75
        • Kereiakes D.J.
        • Berkowitz S.D.
        • Lincoff A.M.
        • et al.
        Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
        Am Heart J. 2000; 140: 74-80
        • Makoni S.N.
        Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
        Heart. 2001; 86: E18
        • McClure M.W.
        • Berkowitz S.D.
        • Sparapani R.
        • et al.
        Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
        Circulation. 1999; 99: 2892-2900
        • Nagge J.
        • Jackevicius C.
        • Dzavik V.
        • Ross J.R.
        • Seidelin P.
        Acute profound thrombocytopenia associated with eptifibatide therapy.
        Pharmacotherapy. 2003; 23: 374-379
        • Sideris S.K.
        • Bonios M.J.
        • Eftihiadis E.E.
        • et al.
        Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.
        Hellenic J Cardiol. 2005; 46: 242-246
        • Bovill E.G.
        • Terrin M.L.
        • Stump D.C.
        • et al.
        Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
        Ann Intern Med. 1991; 115: 256-265
        • Harrington R.A.
        • Sane D.C.
        • Califf R.M.
        • et al.
        The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction.
        J Am Coll Cardiol. 1994; 23: 891-898
        • Best P.J.
        • Mathew V.
        • Markovic S.N.
        Clopidogrel-associated autoimmune thrombocytopenic purpura.
        Catheter Cardiovasc Interv. 2004; 62: 339-340
        • Mehran R.
        • Rao S.V.
        • Bhatt D.L.
        • et al.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
        Circulation. 2011; 123: 2736-2747
        • Spoon D.B.
        • Psaltis P.J.
        • Singh M.
        • et al.
        Trends in cause of death after percutaneous coronary intervention.
        Circulation. 2014; 129: 1286-1294
        • Lin D.Y.
        • Psaty B.M.
        • Kronmal R.A.
        Assessing the sensitivity of regression results to unmeasured confounders in observational studies.
        Biometrics. 1998; 54: 948-963
        • Overgaard C.B.
        • Ivanov J.
        • Seidelin P.H.
        • Todorov M.
        • Mackie K.
        • Dzavik V.
        Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention.
        Am Heart J. 2008; 156: 120-124
        • Levine G.N.
        • Bates E.R.
        • Blankenship J.C.
        • et al.
        American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
        J Am Coll Cardiol. 2011; 58: e44-e122
        • Valgimigli M.
        • Gagnor A.
        • Calabró P.
        • et al.
        • MATRIX Investigators
        Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.
        Lancet. 2015; 385: 2465-2476
        • Topol E.J.
        • Moliterno D.J.
        • Herrmann H.C.
        • et al.
        • TARGET Investigators
        Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
        N Engl J Med. 2001; 344: 1888-1894